Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.
about
Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domainCharacterization of Promiscuous Binding of Phosphor Ligands to Breast-Cancer-Gene 1 (BRCA1) C-Terminal (BRCT): Molecular Dynamics, Free Energy, Entropy and Inhibitor DesignSmall molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseasesUnravelling the genomic targets of small molecules using high-throughput sequencing.Casitas B-Lineage Lymphoma RING Domain Inhibitors Protect Mice against High-Fat Diet-Induced Obesity and Insulin ResistanceIrreversible binding of an anticancer compound (BI-94) to plasma proteins.It takes two to tango: Ubiquitin and SUMO in the DNA damage response.Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.Structural mechanisms underlying signaling in the cellular response to DNA double strand breaks.Targeting homologous recombination-mediated DNA repair in cancer.Embracing synthetic lethality of novel anticancer therapies.The RhoJ-BAD signaling network: An Achilles' heel for BRAF mutant melanomasDiscovery of cell-permeable inhibitors that target the BRCT domain of BRCA1 protein by using a small-molecule microarray.RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment.Discovery and characterization of small molecule Rac1 inhibitors
P2860
Q28256541-410B3F99-5E9B-4EC9-8A78-82ABBA4A5926Q28553736-B3419597-769A-4303-AABA-317899A8659EQ35224775-23FAB9A6-F104-4003-9E19-92A0EDE47338Q35328171-359E00A8-D92F-4569-A5D5-3CACD2FDFE3DQ35752439-55BBAF79-BEB7-4A39-8A28-8B297E7F1A24Q36005906-B5743793-BA92-4B1A-9013-0626FBFEC4A2Q36917433-256397D3-AAA2-49CD-A850-49A0EDBFE84EQ37244880-27AC0B05-FB78-4A67-8550-76510B0B66F9Q37282157-B34DB5AF-2B36-4290-A1E4-E6674C446FE4Q38184667-199A0521-6A1A-4A91-A721-871C808685A3Q38554530-6938DEAB-3794-47A9-9BD8-B1BC55368EA9Q38696187-054C08F9-587B-47AA-9AE8-66DFB00BBE88Q39170653-D6D265E5-959F-4807-91AE-2427E26A9CB1Q42079499-21D2D95C-7DE4-47B7-A5D7-E63D560142E9Q42117338-529CD911-E556-48B8-859A-0251682E6C69
P2860
Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Inhibition of BRCT(BRCA1)-phos ...... tic lethal therapeutic option.
@ast
Inhibition of BRCT(BRCA1)-phos ...... tic lethal therapeutic option.
@en
type
label
Inhibition of BRCT(BRCA1)-phos ...... tic lethal therapeutic option.
@ast
Inhibition of BRCT(BRCA1)-phos ...... tic lethal therapeutic option.
@en
prefLabel
Inhibition of BRCT(BRCA1)-phos ...... tic lethal therapeutic option.
@ast
Inhibition of BRCT(BRCA1)-phos ...... tic lethal therapeutic option.
@en
P2093
P2860
P1476
Inhibition of BRCT(BRCA1)-phos ...... tic lethal therapeutic option.
@en
P2093
Tadayoshi Bessho
Ziyan Yuan Pessetto
P2860
P2888
P304
P356
10.1007/S10549-012-2079-4
P407
P577
2012-05-06T00:00:00Z